2015 AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY

P. Patel , D. Shan , L. Styskal , L. Chang , D. H. Wilson , M. J. Conrad , P. Jarolim
Quanterix Corporation, Lexington, MA, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Introduction: Ultra-sensitive cardiac troponin measurement offers a promising new tool for early detection and monitoring of cardiovascular disease. With growing interest in exploring as an early indicator of adverse heart health trends, the ability to quantitate troponin in healthy control populations is emerging as a highly desirable assay capability. We report analytical data from a fully automated digital immunoassay for cardiac troponin I (cTnI) based on Single Molecule Array (Simoa) technology with a limit of detection 2 logs lower than contemporary high sensitivity troponin assays.